FULC Stock Forecast: Fulcrum Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. hold a median 12-month price target of $4 — +8.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Fulcrum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (73): Sales and profits are climbing, and climbing faster than before.
Momentum (24): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FULC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FULC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.4% from it.
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | JP Morgan | Downgrade | Underweight | — |
| 2 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | $25 → $3.00 |
| 2 June 2026 | Leerink Partners | Downgrade | Market Perform | $24 → $4.00 |
| 2 June 2026 | Piper Sandler | Downgrade | Underweight | $23 → $3.00 |
| 2 June 2026 | Stifel | Downgrade | Hold | $25 → $3.00 |
| 2 June 2026 | Truist Securities | Downgrade | Hold | $17 → $4.00 |
| 12 Jan 2026 | JP Morgan | Initiates | Overweight | — |
| 11 Dec 2025 | Truist Securities | Maintains | Buy | — |
| 9 Dec 2025 | B of A Securities | Maintains | Underperform | — |
| 8 Dec 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 8 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2025 | Piper Sandler | Reiterates | Overweight | — |
| 8 Dec 2025 | RBC Capital | Maintains | Sector Perform | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Nov 2025 | Truist Securities | Initiates | Buy | — |
| 30 Oct 2025 | Piper Sandler | Reiterates | Overweight | — |
| 30 Oct 2025 | RBC Capital | Maintains | Sector Perform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 July 2025 | RBC Capital | Maintains | Sector Perform | — |
| 29 July 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FULC.
This page is one stock. Monday covers all of them.
FULC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FULC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Fulcrum Therapeutics, Inc. returned −66.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FULC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −30.5%
- Return on assets
- −18.1%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fulcrum Therapeutics, Inc. has a market value of $286.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$85.0M.
Diluted earnings per share, trailing twelve months: −$1.21.
Free cash flow in the twelve months to 30 June 2026: −$66.1M.
Fulcrum Therapeutics, Inc. employs 55 people.
Data provided by Twelve Data
FULC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FULC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Fulcrum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FULC
What is the FULC stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FULC stock a buy right now?
Of the 5 analysts covering Fulcrum Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Fulcrum Therapeutics, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FULC?
As at 21 Nov 2026, Fulcrum Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).
Will FULC stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +8.4% from the last close, and Ticker Nerd's factor model ranks Fulcrum Therapeutics, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FULC stock forecast for 2030?
No analyst covering Fulcrum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FULC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.
How has FULC stock performed over the past year?
Fulcrum Therapeutics, Inc. returned -66.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Fulcrum Therapeutics, Inc. do?
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.
CEO Mr. Alexander C. Sapir · 55 employees · United States · https://www.fulcrumtx.com